Rituximab maintenance significantly prolongs progression-free
survival of patients with newly diagnosed mantle cell lymphoma
treated with the Nordic MCL2 protocol and autologous stem cell
transplantation

J 2019

Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation

KLENER, Pavel, David ŠÁLEK, Robert PYTLIK, Heidi MOCIKOVA, Kristina FORSTEROVA et. al.

Základní údaje

Originální název

Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation

Autoři

KLENER, Pavel (203 Česká republika, garant), David ŠÁLEK (203 Česká republika, domácí), Robert PYTLIK (203 Česká republika), Heidi MOCIKOVA (203 Česká republika), Kristina FORSTEROVA (203 Česká republika), Petra BLAHOVCOVA (203 Česká republika), Vit CAMPR (203 Česká republika), Vit PROCHAZKA (203 Česká republika), Ales OBR (203 Česká republika), Radek JAKSA (203 Česká republika), Jana KUNTSCHEROVA (203 Česká republika), Ludmila BOUDOVA (203 Česká republika), Roman KODET (203 Česká republika), Andrea JANÍKOVÁ (203 Česká republika, domácí) a Marek TRNENY (203 Česká republika)

Vydání

American Journal of Hematology, Hoboken, John Wiley & Sons, 2019, 0361-8609

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.973

Kód RIV

RIV/00216224:14110/19:00112784

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1002/ajh.25362

UT WoS

000455234700005

Klíčová slova anglicky

FOLLOW-UP; IMMUNOCHEMOTHERAPY

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 28. 1. 2020 09:42, Mgr. Tereza Miškechová

Anotace

V originále

Mantle cell lymphoma (MCL) is still considered to be an incurable subtype of B-NHL, but the outcome is improving and the implementation of anti-CD20 rituximab and high-dose cytarabine (HDAC) into E50 CORRESPONDENCE induction therapy, consolidation with high-dose therapy and autologous stem cell transplant (ASCT), and rituximab maintenance (RM) are currently considered standard approaches for all transplant-eligible patients. Recently, progression free survival (PFS) and overall survival (OS) benefit of RM were confirmed in patients (pts) with MCL treated with R-DHAP and ASCT.1 Whether RM improves outcomes in patients treated with other induction regimens is unknown. As part of the NiHiL observational study in patients with malignant lymphomas (GovTrial No. NCT03199066), we analyzed outcome of 143 consecutive patients with newly diagnosed MCL treated with the Nordic MCL2 protocol followed by ASCT and RM or observation.2,3 The study was approved by the Ethics Committee of the Charles University General Hospital in Prague under number 1816/15S-IV. Further details are described in the Supplemental Methods.

Citovat

KLENER, Pavel, David ŠÁLEK, Robert PYTLIK, Heidi MOCIKOVA, Kristina FORSTEROVA, Petra BLAHOVCOVA, Vit CAMPR, Vit PROCHAZKA, Ales OBR, Radek JAKSA, Jana KUNTSCHEROVA, Ludmila BOUDOVA, Roman KODET, Andrea JANÍKOVÁ a Marek TRNENY. Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. American Journal of Hematology. Hoboken: John Wiley & Sons, 2019, roč. 94, č. 2, s. "E50"-"E53", 4 s. ISSN 0361-8609. Dostupné z: https://dx.doi.org/10.1002/ajh.25362.

@article{1612157,
   author = {Klener, Pavel and Šálek, David and Pytlik, Robert and Mocikova, Heidi and Forsterova, Kristina and Blahovcova, Petra and Campr, Vit and Prochazka, Vit and Obr, Ales and Jaksa, Radek and Kuntscherova, Jana and Boudova, Ludmila and Kodet, Roman and Janíková, Andrea and Trneny, Marek},
   article_location = {Hoboken},
   article_number = {2},
   doi = {http://dx.doi.org/10.1002/ajh.25362},
   keywords = {FOLLOW-UP; IMMUNOCHEMOTHERAPY},
   language = {eng},
   issn = {0361-8609},
   journal = {American Journal of Hematology},
   title = {Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation},
   url = {http://dx.doi.org/10.1002/ajh.25362},
   volume = {94},
   year = {2019}
}

TY  - JOUR
ID  - 1612157
AU  - Klener, Pavel - Šálek, David - Pytlik, Robert - Mocikova, Heidi - Forsterova, Kristina - Blahovcova, Petra - Campr, Vit - Prochazka, Vit - Obr, Ales - Jaksa, Radek - Kuntscherova, Jana - Boudova, Ludmila - Kodet, Roman - Janíková, Andrea - Trneny, Marek
PY  - 2019
TI  - Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation
JF  - American Journal of Hematology
VL  - 94
IS  - 2
SP  - "E50"-"E53"
EP  - "E50"-"E53"
PB  - John Wiley & Sons
SN  - 03618609
KW  - FOLLOW-UP
KW  - IMMUNOCHEMOTHERAPY
UR  - http://dx.doi.org/10.1002/ajh.25362
L2  - http://dx.doi.org/10.1002/ajh.25362
N2  - Mantle cell lymphoma (MCL) is still considered to be an incurable subtype of B-NHL, but the outcome is improving and the implementation of anti-CD20 rituximab and high-dose cytarabine (HDAC) into E50 CORRESPONDENCE induction therapy, consolidation with high-dose therapy and autologous stem cell transplant (ASCT), and rituximab maintenance (RM) are currently considered standard approaches for all transplant-eligible patients. Recently, progression free survival (PFS) and overall survival (OS) benefit of RM were confirmed in patients (pts) with MCL treated with R-DHAP and ASCT.1 Whether RM improves outcomes in patients treated with other induction regimens is unknown. As part of the NiHiL observational study in patients with malignant lymphomas (GovTrial No. NCT03199066), we analyzed outcome of 143 consecutive patients with newly diagnosed MCL treated with the Nordic MCL2 protocol followed by ASCT and RM or observation.2,3 The study was approved by the Ethics Committee of the Charles University General Hospital in Prague under number 1816/15S-IV. Further details are described in the Supplemental Methods.
ER  -

KLENER, Pavel, David ŠÁLEK, Robert PYTLIK, Heidi MOCIKOVA, Kristina FORSTEROVA, Petra BLAHOVCOVA, Vit CAMPR, Vit PROCHAZKA, Ales OBR, Radek JAKSA, Jana KUNTSCHEROVA, Ludmila BOUDOVA, Roman KODET, Andrea JANÍKOVÁ a Marek TRNENY. Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. \textit{American Journal of Hematology}. Hoboken: John Wiley \&{} Sons, 2019, roč.~94, č.~2, s.~''E50''-''E53'', 4 s. ISSN~0361-8609. Dostupné z: https://dx.doi.org/10.1002/ajh.25362.

Podrobný výpis o publikaci